Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)

Who May Qualify: - Histopathologically confirmed CD20 positive B-cell lymphoma; - Plan to receive first-line anti-lymphoma therapy containing CD20 monoclonal antibodies; - Negative HBsAg, HBV-DNA lower than the detection limit and positive anti-HBC at baseline; - Total bilirubin less than 1.5X the upper limit of normal (ULN), AST and ALT less than 2.5X ULN; - ECOG PS: 0\~2; - Estimated survival time \>3 months. Who Should NOT Join This Trial: - Positive HBsAg or HBV-DNA higher than the detection limit at baseline; - Previous chemotherapy or radiotherapy for lymphoma; - Other primary liver diseases, such as chronic hepatitis C, hepatitis D, autoimmune hepatitis, Wilson' s disease or primary biliary cirrhosis; - Pregnant or lactating women; - History of weakened immune system, including positive HIV, or other acquired congenital weakened immune system disease, or history of organ transplantation. Always talk to your doctor about whether this trial is right for you.